These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32863287)

  • 1. Increased Serum Malondialdehyde-Modified Low-Density Lipoprotein and Coronary Angiographic Progression After Drug-Eluting Stent Implantation in Patients With Stable Angina.
    Yokoi M; Ito T; Fujita H; Sugiura T; Seo Y; Ohte N
    Circ J; 2020 Sep; 84(10):1837-1845. PubMed ID: 32863287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent.
    Ito T; Fujita H; Tani T; Ohte N
    Atherosclerosis; 2015 Apr; 239(2):311-7. PubMed ID: 25682029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of malondialdehyde-modified low-density lipoprotein on coronary plaque vulnerability in patients not receiving lipid-lowering therapy: a whole coronary analysis with multislice-computed tomography.
    Ito T; Ichihashi T; Fujita H; Sugiura T; Ohte N
    Heart Vessels; 2018 Apr; 33(4):351-357. PubMed ID: 29067491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Amioka N; Miyoshi T; Otsuka H; Yamada D; Takaishi A; Ueeda M; Hirohata S; Ito H
    J Cardiol; 2019 Sep; 74(3):258-266. PubMed ID: 30898480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus.
    Kotani K; Tashiro J; Yamazaki K; Nakamura Y; Miyazaki A; Bujo H; Saito Y; Kanno T; Maekawa M
    Clin Chim Acta; 2015 Oct; 450():145-50. PubMed ID: 26265234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of malondialdehyde-modified low-density lipoprotein on clinical outcomes after fractional flow reserve-guided deferral of revascularization.
    Yokoi M; Ito T; Fujita H; Sugiura T; Seo Y; Ohte N
    Heart Vessels; 2021 May; 36(5):605-614. PubMed ID: 33219835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased circulating malondialdehyde-modified low-density lipoprotein levels in patients with ergonovine-induced coronary artery spasm.
    Ito T; Fujita H; Tani T; Sugiura T; Ohte N
    Int J Cardiol; 2015 Apr; 184():475-480. PubMed ID: 25756568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation.
    Zhong Z; Hou J; Zhang Q; Zhong W; Li B; Li C; Liu Z; Yang M; Zhao P
    Lipids Health Dis; 2019 Feb; 18(1):40. PubMed ID: 30711009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial coronary computed tomography angiography-verified coronary plaque progression: comparison of stented patients with or without diabetes.
    Shi R; Shi K; Yang ZG; Guo YK; Diao KY; Gao Y; Zhang Y; Huang S
    Cardiovasc Diabetol; 2019 Sep; 18(1):123. PubMed ID: 31551077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional Effect of Coronary High-Intensity Plaque on T1-Weighted Magnetic Resonance Imaging With Circulating Malondialdehyde-Modified Low-Density Lipoprotein on Cardiac Events.
    Hiraya D; Sato A; Hoshi T; Sakai S; Watabe H; Ieda M
    Circ J; 2021 Oct; 85(11):2032-2039. PubMed ID: 34275962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observational Prospective study to esTIMAte the rates of outcomes in patients undergoing PCI with drug-eluting stent implantation who take statins -follow-up (OPTIMA II).
    Karpov Y; Logunova N; Tomilova D; Buza V; Khomitskaya Y
    Curr Med Res Opin; 2017 Feb; 33(2):253-259. PubMed ID: 27779436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malondialdehyde-Modified Low Density Lipoprotein as Oxidative-Stress Marker in Vasospastic Angina Patients.
    Oumi T; Nozato T; Sakakibara A; Nomoto H; Ohno M; Takahashi Y; Ashikaga T; Satoh Y; Isobe M
    Int Heart J; 2017 May; 58(3):335-343. PubMed ID: 28539572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation.
    Wu Y; Fu X
    J Clin Lab Anal; 2019 Feb; 33(2):e22666. PubMed ID: 30221497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease.
    Matsuo Y; Kubo T; Okumoto Y; Ishibashi K; Komukai K; Tanimoto T; Ino Y; Kitabata H; Hirata K; Imanishi T; Akagi H; Akasaka T
    Eur Heart J Cardiovasc Imaging; 2013 Jan; 14(1):43-50. PubMed ID: 22573905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malondialdehyde-modified low-density lipoprotein is a useful marker to identify patients with vulnerable plaque.
    Tajika K; Okamatsu K; Takano M; Inami S; Yamamoto M; Murakami D; Kobayashi N; Ohba T; Hata N; Seino Y; Mizuno K
    Circ J; 2012; 76(9):2211-7. PubMed ID: 22785057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing statin treatment.
    Sakai R; Sekimoto T; Koba S; Mori H; Matsukawa N; Arai T; Yokota Y; Sato S; Tanaka H; Masaki R; Oishi Y; Ogura K; Arai K; Nomura K; Sakai K; Tsujita H; Kondo S; Tsukamoto S; Suzuki H; Shinke T
    J Clin Lipidol; 2023; 17(2):281-290. PubMed ID: 36828767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-coated balloon versus drug-eluting stent in small coronary artery lesions: angiographic analysis from the BASKET-SMALL 2 trial.
    Fahrni G; Scheller B; Coslovsky M; Gilgen N; Farah A; Ohlow MA; Mangner N; Weilenmann D; Wöhrle J; Cuculi F; Leibundgut G; Möbius-Winkler S; Zweiker R; Twerenbold R; Kaiser C; Jeger R;
    Clin Res Cardiol; 2020 Sep; 109(9):1114-1124. PubMed ID: 31993736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in serum malondialdehyde-modified low-density lipoprotein in patients with acute myocardial infarction and stable angina pectoris treated by coronary angioplasty].
    Araki T; Kanaya H; Shimizu M; Mabuchi H; Kitayama M; Kanemitsu S; Takekoshi N;
    J Cardiol; 2001 Aug; 38(2):55-60. PubMed ID: 11525110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of atherosclerotic disease progression using LDL transport modelling: a serial computed tomographic coronary angiographic study.
    Sakellarios A; Bourantas CV; Papadopoulou SL; Tsirka Z; de Vries T; Kitslaar PH; Girasis C; Naka KK; Fotiadis DI; Veldhof S; Stone GW; Reiber JH; Michalis LK; Serruys PW; de Feyter PJ; Garcia-Garcia HM
    Eur Heart J Cardiovasc Imaging; 2017 Jan; 18(1):11-18. PubMed ID: 26985077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.
    Liistro F; Porto I; Angioli P; Grotti S; Ducci K; Falsini G; Bolognese L
    Am Heart J; 2013 Nov; 166(5):920-6. PubMed ID: 24176449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.